Skip to main content

Table 2 Naringenin's impact on the movement of ranolazine from the rat-everted ileum's mucosal to serosal side (n = 6)

From: Naringenin alters the pharmacokinetics of ranolazine in part through the inhibition of cytochrome P450 (3A4) and P-glycoprotein

Time (min)

Ranolazine (50 μM)

Ranolazine (50 μM) + naringenin(10 μM)

Ranolazine (50 μM) + naringenin (50 μM)

Ranolazine (50 μM) + naringenin (100 μM)

Ranolazine (50 μM) + naringenin (200 μM)

10

10.01 ± 1.49

10.62 ± 1.31*

12.23 ± 1.24*

14.97 ± 1.03*

15.34 ± 1.52

20

14.1 ± 1.03

17.98 ± 1.13*

19.9 ± 1.54*

22.99 ± 1.56*

22.96 ± 1.6

30

20.41 ± 1.98

22.22 ± 1.43*

24.58 ± 1.05*

26.84 ± 1.41*

26.44 ± 1.36

40

21.81 ± 2.11

24.74 ± 1.36*

26.8 ± 1.21*

28.31 ± 1.14*

29.6 ± 2.02

50

21.42 ± 2.32

26.78 ± 1.26*

28.87 ± 1.94

29.93 ± 1.53*

31.28 ± 2.79

60

20.95 ± 2.01

27.37 ± 1.38*

29.28 ± 1.68*

30.83 ± 2.00*

31.06 ± 2.19

  1. *p < 0.05, when compared to ranolazine treatment alone